2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 793

Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 88

Mind Map Use in Rheumatology Education

Education Poster

9:00AM-11:00AM: Abstract Number: 567

Minor Salivary Gland Histopathology, Major Salivary Gland Ultrasonography, and Secretory Function in Smoking Patients with Primary Sjögren’s Syndrome

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 643

Mir-10b-5p Is a IL-22 Regulator in CD4+T Cells from Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 63

MiR-146a a Key Player in Bone Metabolism

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 301

MiR-221-3p Overexpression Impairs Anti-Inflammatory Activity of TLR4-Stimulated M2-Macrophages

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 48

Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality

Biology and Pathology of Bone and Joint Poster I

9:00AM-11:00AM: Abstract Number: 564

Molecular Identification of a Ro-Specific Salivary IgA Repertoire with Unique Clonal Signatures in Primary Sjogren’s Syndrome

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 772

Molecular Mechanism for the Therapeutic Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers of Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 477

Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 504

Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 812

Mortality Risk and Cause-Specific Mortality in Polymyalgia Rheumatica: A Population-Based Cohort Study

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 235

MRI in Rheumatoid Arthritis: Does Quantifying the Number of Erosive Lesions Improve Detection of Subtle Erosive Progression Compared to the Omeract RA MRI Scoring System?

Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 759

Multi Dimensional Analysis of the Immunome in Systemic Sclerosis Reveals Functionally Related Abnormalities in MAIT and B Cell Compartments

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 414

Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].